Abstract

Background: Rare disease patients and carers report significant impacts on mental health but studies on UK populations have focussed on relatively few, specific conditions. Collectively rare conditions represent a substantial health burden, with an estimated 3.5 million affected individuals in the UK.

Method: We explored the impact on mental health of living with a rare condition, and experiences of health service support, through an online survey. The survey assessed the impact of specific experiences commonly reported by those affected by a rare condition through multiple choice questions and Likert scale items, and open text question boxes. Through a multi-stakeholder workshop that involved facilitated discussion of our findings with patients/carers, clinicians and a government advisor, we developed recommendations for policy and practice toward a more person-centred and integrated approach.

Results: Eligible responses came from 1231 patients and 564 carers. Due to their rare condition, the majority of respondents (> 90%) had felt worried/anxious; stressed; and/or low/depressed. Thirty-six percent of patients and 19% of carers had had suicidal thoughts. Challenges that are particular to rare conditions and which negatively affect mental health included limited knowledge of the condition amongst healthcare professionals (88%), and not being believed or taken seriously by them. Only 23% of respondents felt healthcare professionals considered mental and physical health as equally important. Almost half reported never having been asked about mental health by healthcare professionals. Our findings indicate that access to, and appropriateness of, professional psychological support needs to be improved. Peer group support is important but signposting is inadequate.

Our recommendations are for healthcare professionals to be supported to effectively and sensitively recognise and address patients’ and carers’ mental health needs; and for service level coordination of care to integrate professional psychological support with rare disease services.

Conclusion: Living with a rare disease substantially impacts mental health. Many of the drivers of poor mental health reflect issues specific to managing rare conditions. To meet UK government commitments, there should be a focus on empowering healthcare professionals who treat rare disease patients and on integration of mental health support with rare disease services.

Keywords: Rare disease, Undiagnosed, Mental health, Health service, Patient experience, Survey, Recommendations
Background

Although rare conditions by definition affect no more than 1 in 2000 individuals [1], there are over 6000 known conditions so that collectively they represent a substantial health burden, with an estimated 3.5 million affected individuals in the UK [2]. Studies of the psychological consequences of living with a rare condition for UK patients as a collective cohort are restricted to non-peer reviewed reports [3, 4]. Australian and American rare disease patient populations have been better studied and findings illustrate clear psychosocial and health-related quality of life impacts [5–9]. Recently a systematic review and meta-analysis of affective and anxiety disorders in adult patients with rare conditions reported prevalence estimates higher than the general population [10].

Further evidence is available from qualitative studies, which have generally indicated impaired emotional/psychological wellbeing for carers as well as patients. For example, psychological consequences have been reported amongst individuals, and parents/carers, living with undiagnosed or medically unexplained conditions [11, 12]; and parents/carers of individuals with specific diagnosed conditions [13–15].

Rare Disease UK’s survey of 1203 patients and carers reported numerous psychological consequences, yet the majority of respondents did not feel they received sufficient psychological support [4]. Similarly, of the 30 Australian families affected by rare disease that were surveyed by Anderson et al., the majority reported high levels of psychological stress but few had received psychological support [5].

Current literature does not provide a good understanding of the impact on mental health specifically in the UK, and in particular the impact of the support offered by the UK health services, for those affected by or caring for someone with any rare disease. The majority of the available evidence is condition-specific and/or is confined to validated tools that are time-restricted and do not provide information about patients’ and carers’ past experiences. We wanted to address this gap in knowledge by the UK health services, for those affected by or carers of individuals with rare disease [20, 21]. An advisory group provided guidance on the survey development. The group included rare disease patients and carers, clinicians, a representative from a national mental health charity and a social science researcher. Data were handled in line with current data protection legislation. Descriptive statistics were generated from the data after cleaning to remove ineligible respondents and skipped questions, and the findings were used to create draft recommendations. The findings of the survey and interviews were discussed at a multi-stakeholder workshop in order to develop specific recommendations for change in policy and practice.

Methods

A schematic of the project method is shown in Fig. 1.

The elements in the survey were derived from: a review of relevant literature; a call for relevant information from members of Genetic Alliance UK (over 200 patient groups); and thematic analysis of transcripts from eight interviews with rare disease patients and eight interviews with carers about the impact of rare disease on mental health and their experiences of mental health support [20, 21]. An advisory group provided guidance on the survey development. The group included rare disease patients and carers, clinicians, a representative from a national mental health charity and a social science researcher. Data were handled in line with current data protection legislation. Descriptive statistics were generated from the data after cleaning to remove ineligible respondents and skipped questions, and the findings were used to create draft recommendations. The findings of the survey and interviews were discussed at a multi-stakeholder workshop in order to develop specific recommendations for change in policy and practice.

Survey elements

The survey measured respondents’ self-assessments of their experience related to the following themes (for themselves or the person they care for): the emotional impact of rare disease; stressors and promoters of mental health; evaluation of care received; professional psychological support; other sources of support. Diagnostic information, whether the respondent was a patient or carer, the age of the person cared for, and respondent demographics were also collected.

The majority of the survey questions were quantitative and fixed-choice. Question types included single answers, multiple choice, and Likert scale items. A small number of questions included free-text responses.

The survey also included questions used in a previous study developed by The Neurological Alliance with their permission, an adaptation of the Short Warwick–Edinburgh Mental Well-being Scale (SWEMWBS), @ NHS Health Scotland, University of Warwick and University of Edinburgh), and items from the Multidimensional Scale of Perceived Social Support (MSPSS) [22–24]. The
mixed-methods approach ensured the survey questions were relevant to the research question, and offered support for the survey findings through triangulation of results [25]. The survey was piloted with patients and carers and staff members of Genetic Alliance UK (five individuals in total). Volunteers piloted the survey in their own time and provided written or verbal feedback on comprehensiveness, sensitivity, relevance and ease of completion. Additional comments or suggestions were also encouraged. Amendments were made after discussion of the pilot with the advisory group.

Recruitment
A link to the online survey was sent to members of Genetic Alliance UK; Rare Disease UK supporters (over 2000, including individuals and patient groups); and members of SWAN UK (syndromes without a name) which included more than 1800 families of children with an undiagnosed condition and more than 600 professionals. The online survey was also shared on social media to increase our reach to individuals beyond our immediate networks. The survey was hosted on SurveyMonkey and was live for a total of 28 days in November and December 2017.

Those eligible to take part were aged 18+, based in the UK, and either a patient with a rare disease, or a parent/carer. A set of screening questions ensured respondents met the eligibility criteria. Informed consent was obtained from all subjects via a consent box, which had to be ticked before the survey could be taken. Respondents

**Fig. 1 Flow chart of project methods**

- Literature scoping exercise
  - Reviewed published literature
  - Put out a call for information from members of Genetic Alliance UK (200+ patient organisations)

- Advisory group formed
  - Included rare disease patients and carers, clinicians, a representative from a national mental health charity and a social science academic

- Ethics approval granted
  - From National Social Care Research Ethics Committee

- Interviews conducted
  - 8 patients, 8 carers
  - Semi-structured interviews
  - Findings analysed using thematic analysis

- Survey development
  - Discussed findings of literature scoping exercise and interviews with advisory group
  - Identified relevant tools/questions from literature for use in survey
  - Piloted survey with five individuals
  - Discussed feedback with advisory group, agreed amendments made

- Survey is live
  - November - December 2017
  - 1,926 individuals responded; 1,795 total respondents eligible to take part (1,231 patients, 564 carers)
  - Descriptive statistical analysis to analyse findings

- Stakeholder workshop held
  - Included representatives from patient organisations and health professional organisations/bodies, and individual clinicians, patients and carers
  - Discussed project findings, including practice and service implications.
had the option to withhold consent for the use of direct quotes from any free-text responses.

**Development of recommendations**

Recommendations were drafted by the authors in response to the survey findings with the aim of improving services through empowering healthcare professionals and service-level coordination. The recommendations were refined through consultation at a multi-stakeholder workshop with 16 attendees including a psychologist, a behavioural therapist, representatives of rare disease patient organisations and mental health charities, individual patients and carers, representatives of professional bodies for healthcare professionals, academics, and a member of a government advisory committee.

The findings from the pre-survey interviews and from the survey were presented, followed by the draft recommendations, in order to stimulate constructive engagement. A whole-group discussion was facilitated to refine each recommendation to make sure they were achievable and specific. Notes of the discussion were taken by three note-takers. The notes were combined, then checked and refined collaboratively by the authors. The resulting text was marked up as relevant to policy and practice (relating to individual healthcare professionals or to service-level organisation), or out of scope. The recommendations were revised in light of the workshop report.

**Results**

1. **Respondent characteristics.** Of the eligible respondents (1231 patients, 564 carers), completion rate was 69% for patients (913/1231) and 60% for carers (340/564). The skew toward female respondents is slightly greater for carers (92.4%, 315/341) than for patients (83.9%, 778/927). The high numbers of white British responses (94.8%, 1202/1268) is over-representative for the UK while other ethnicities were under-represented [26]. The four nations of the UK were represented in the sample approximately in proportion with population figures. The ages of respondents, and of the person looked after by respondents who are carers, are given in Tables 1 and 2.

We presented an open text response box to collect as much diagnostic information as possible, and manually classified responses using the ERN (European Reference Networks) categories as a framework [27]. Most respondents fell under a single category. There was a relatively high proportion of respondents representing immunological, neurological, connective tissue, neuromuscular and endocrine conditions. Among the carers’ there was a proportion of conditions categorised as congenital malformations and intellectual disability (including undiagnosed conditions with a suspected genetic origin, and chromosomal abnormalities). Some condition categories had little or no representation, including respiratory diseases, urogenital diseases, and paediatric cancer. Such a profile, while introducing a level of bias, is not unexpected given the dissemination method used.

**The nature of the emotional impact**

**Feelings and emotions**

Respondents were given a list of thoughts and feelings and asked to rate each in terms of their experience of living with, or caring for someone with, a rare condition. Figure 2 illustrates the range of negative emotions that respondents reported. Almost all indicated that, as a result of the rare condition, they had felt (some of the time/often/all of the time): worried or anxious (95%, 1604/1688), stressed (93%, 1578/1689), emotional (92%, 1556/1685), low or depressed (90%, 1509/1683), angry or frustrated (90%, 1514/1690), emotionally exhausted (88%, 1485/1686), or alone (83%, 1403/1684). Thirty-six percent of patients (434/1194) and 19% of carers (92/496) had experienced thoughts about suicide (some of the time/often/all of the time).

Respondents had also experienced positive thoughts and feelings although this was less marked than for the negative feelings. The majority of respondents reported that, in relation to the rare condition, they had (some of the time/often/all of the time): been able to make up their

| Table 1 Age of survey respondents |
|-----------------------------------|
| **Age** | **Respondents: patients n (%)** | **Respondents: carers n (%)** | **Total respondents: n (%)** |
| 18–24 | 61 (6.6) | 0 (0) | 61 (4.8) |
| 25–40 | 265 (28.5) | 144 (42.0) | 409 (32.1) |
| 41–60 | 452 (48.6) | 174 (50.7) | 626 (49.2) |
| 61+ | 147 (15.8) | 19 (5.5) | 166 (13.0) |
| I’d prefer not to say | 5 (0.5) | 6 (1.7) | 11 (0.9) |
| **Total** | 930 | 343 | 1273 |

| Table 2 Age of person cared for by respondents |
|-----------------------------------------------|
| **Age of person cared for** | **Total n (%)** |
| 0–3 | 58 (16.9) |
| 4 to 11 | 122 (35.6) |
| 12 to 17 | 61 (17.8) |
| 18+ | 94 (27.4) |
| I’d prefer not to say | 8 (2.3) |
| **Total** | 343 |
mind (86%, 1455/1690), had been thinking clearly (77%, 1290/1683), had been dealing with problems well (77%, 1291/1688), feeling useful (62%, 1048/1679), close to others (60%, 1012/1684) and optimistic about the future (59%, 996/1687). Fewer than half of respondents (44%, 747/1685) reported feeling relaxed; the percentage was lower for carers (34%, 170/498) than for patients (49%, 577/1187).

Times that have had a negative impact on emotional health and wellbeing
The majority of survey respondents reported (agree/strongly agree) that the following periods of time had negatively impacted mental health: the day-to-day challenges of living with the condition (88%, 1367/1559), onset of symptoms (84%, 1290/1530), trying to get a diagnosis (83%, 1235/1490), coming to terms with the condition or diagnosis (83%, 1247/1506), thinking ahead to the future (82%, 1272/1558) and when a diagnosis was given (70%, 991/1418).

Knock-on impact of poor mental health
Respondents indicated that poor mental health had negatively impacted other aspects of life (agree/strongly agree). This included a knock-on impact on physical health (87%, 1242/1420), on work or studies (81%, 995/1222); and on personal relationships with partners (76%, 984/1292), friends (71%, 999/1414), and relatives (69%, 979/1411).

Factors affecting mental health
The specific factors explored in relation to mental health can be grouped into three categories: i) interactions with healthcare professionals and services, ii) everyday living with a rare condition, and iii) additional factors for carers.

Interactions with healthcare professionals and services
Respondents reported that aspects of their interactions with healthcare professionals had negatively impacted mental health (Fig. 3 panel A). Many of the factors identified were related to the rarity of the condition. For example, the most frequently identified factor (agree/strongly agree) was lack of awareness of the condition among healthcare professionals (88%, 1308/1486), followed by not being believed or taken seriously (80%, 1158/1444), and being treated as a medical curiosity (50%, 714/1433).

Factors relating to service access and coordination were also reported to negatively impact mental health (Fig. 3 panel B). This included (agree/strongly agree): trying to access health services or treatments (80%, 1183/1487), the way care is coordinated or organised between different departments or services (79%, 1161/1469), accessing financial support such as disability living allowance (76%, 951/1254), and accessing other support such as social care or respite care (72%, 945/1319).

Everyday living with a rare condition
Factors that are specific to everyday living with a rare condition were also reported to have impacted
respondents’ mental health (agree/strongly agree): lack of understanding about the condition among the public (90%, 1313/1458), feeling uncertain about what the future holds (87%, 1279/1469), having to explain the condition to other people (81%, 1191/1472), and lack of available information about the condition (76%, 1096/1448). Over half of respondents (56%, 792/1411) identified worry -ing information they had come across online as a factor affecting mental health.

For context we asked respondents about other stressors in their lives. A large majority of respondents reported (agree/strongly agree) that major life events (86%, 1196/1389), financial pressures and worries (80%, 1059/1327) and feeling socially isolated (76%, 1076/1412) had impacted mental health.

Additional factors for carers
Almost all carers reported that worrying about their child’s quality of life (97%, 370/383), and/or worrying about their child’s emotional wellbeing (96%, 365/381) had affected their own mental health (agree/strongly agree).

Evaluation of care
The survey explored respondents’ experiences of services and how well they felt their emotional and mental health needs had been met.

Services, parity of esteem and information
Figure 4 panel A shows that, when rating the care and treatment they have received, 62% of respondents (852/1382) reported that they were satisfied (fairly satisfied/satisfied/very satisfied) with services to meet their physical health needs, but only 39% (532/1357) were satisfied with services to meet their mental health needs. In response to the statement “I feel my/my child’s mental health is considered equally as important as my/my child’s physical health by healthcare professionals involved in my/my child’s care,” the majority of respondents (60%, 814/1349) chose ‘disagree’ or ‘strongly disagree’. A minority of respondents chose ‘agree’ or ‘strongly agree’ (23%, 316/1349) (Fig. 4 panel B).

Approximately half of respondents were satisfied (fairly satisfied/satisfied/very satisfied) with the information they were given about the physical condition (48%, 653/1367), while fewer respondents (30%, 411/1366) were satisfied with the information provided about sources of emotional support.

Healthcare professionals asking about mental health
Respondents were presented with the statement “healthcare professionals ask about my/my child’s mental and emotional wellbeing”. Almost half of patients (46%, 454/988) and carers (48%, 173/362) chose ‘never’, and just 8% of patients (81/988) and carers (28/362) chose ‘often’ or ‘always’. Of carers, 57% (208/363) reported they
had ‘never’ been asked about their own mental health by healthcare professionals involved in their child’s care.

A proportion of respondents reported (agree/strongly agree) positive experiences when healthcare professionals had discussed mental health and wellbeing with them (Fig. 5): some reported that the discussions were handled sensitively (35%, 377/1068), that they felt genuine (34%, 369/1086) and that they had a positive impact on emotional wellbeing (24%, 252/1066). Conversely respondents also reported (agree/strongly agree) negative experiences when discussing mental health and wellbeing with healthcare professionals (Fig. 5): discussions made them feel anxious (44%, 468/1061); uncomfortable (36%, 386/1060) or made them feel worse (34%, 356/1059).
How to improve care to better support wellbeing and mental health

A large majority of respondents felt the following would improve their mental health (agree/strongly agree): greater awareness of the emotional challenges of living with a rare condition among healthcare professionals (91%, 1184/1308), greater sensitivity among healthcare professionals (85%, 1090/1284), and being asked more frequently about mental health and wellbeing by healthcare professionals (81%, 1056/1296). Respondents also reported that easier access to emotional support would improve their mental health; the majority felt (agree/strongly agree) that easier access to professional psychological support (85%, 1069/1262) and better signposting to alternative sources of emotional support (86%, 1105/1283), would benefit their mental health.

Experiences of professional psychological support

Access and barriers to professional psychological support services

Just over half (54%, 719/1323) of respondents had not accessed any professional psychological support. Of those who had accessed professional psychological support just 7% had accessed it through a specialist clinic for their condition (41/588) and only 2% of respondents (14/588) had been offered professional psychological support at the time of diagnosis of their condition. More respondents had been referred by their GP (48%, 280/588) or clinicians at their hospital (21%, 123/588). A proportion of respondents (18%, 106/588) had accessed private psychological support (i.e. ‘arranged and paid for it myself’). Of these respondents, over half (55%, 58/105) had paid more than £500 in total and a further quarter (26%, 27/105) had paid between £100 and £500.

Respondents identified several factors that had prevented them from accessing professional psychological support. The most commonly reported was that it had not been suggested by healthcare professionals (41%, 527/1285), followed by not being able to afford private psychological support (29%, 372/1285) and that the waiting lists for mental health services were too long (23%, 299/1285). Carers in particular cited too much pressure on their time as being a barrier (22%, 77/350).

Evaluation of professional psychological support

Respondents who had accessed professional psychological support were asked to evaluate that support (Fig. 6). Around half (49%, 282/570) had found it was helpful (agree/strongly agree), but fewer (37%, 209/571) felt it was tailored to their needs (agree/strongly agree).

Over half of respondents (56%, 319/571) reported (agree/strongly agree) they did not have to travel far to access the support. Fewer felt that the support was available when needed (31%, 179/578) or had been easy to access (27%, 155/580) or were confident they would be able to access professional psychological support again if they needed it (34%, 198/580) (agree/strongly agree).

Support from other sources

Fifty-nine percent of respondents (759/1292) reported they had accessed additional emotional support such as peer support online (81%, 617/759) or face-to-face (36%, 274/759) and support from charities or the community sector (25%, 192/759). The majority of respondents (75%, 534/713) who had accessed such support reported having found it themselves. A minority had been signposted to the support by a healthcare professional (18%, 125/713), and the most frequent reason for not accessing such support was not knowing how to access it (41%, 210/516).
Eighteen percent of respondents believed there was no such support available to them (92/516). Respondents indicated (agree/strongly agree) that such sources of support were helpful for several different reasons (Fig. 7).

Over half of respondents (67%, 862/1282) reported that their family ‘really tries to help them’ (agree/strongly agree) but fewer felt that they get the emotional support they need from their family (48%, 612/1281). The equivalent numbers for friends were: 47% (588/1256) and 37% (462/1257).

**Discussion**

**The nature of the emotional impact of rare disease**

The current study is significant in that it is not restricted to a specific rare disease type and has a broad scope of investigation into the UK population of people affected by rare conditions, including the nature of the impact of living with a rare disease, what factors affect mental health, experiences of support and services, and what patients and carers judge would improve mental health support. Our findings demonstrate that rare disease has a substantial negative impact on mental health for both patients and carers. This reflects existing literature on unmet needs [3, 5, 28] and is consistent with findings from condition-specific studies which used diagnostic tools to measure anxiety and/or depression in rare disease patients and/or carers and impact on quality of life [8, 10, 29–32].

Consistent with condition-specific research [32–35], our findings show that the negative impact on mental health can be chronic, and can occur or recur at different times such as during the ‘diagnostic odyssey’; when a diagnosis is given; and while coming to terms with the condition. This highlights the periods when additional emotional support may be particularly important. The impact of the ‘diagnostic odyssey’ is concerning: it can last a long time, with one in four waiting longer than five years for a diagnosis [4] and many will not see the end of this phase, as the diagnostic yield of genome sequencing remains significantly lower than 100% [36]. This means that the mental health of rare disease patients is affected before they are categorically defined as such, and before they might access support through specialist services or disease-specific patient support groups. Other groups have asserted that receiving a rare disease diagnosis can be a particularly emotionally challenging time, in which patients and families experience feelings such as shock, meaning routine psychological support should be offered at the time of diagnosis [5]. It may seem counterintuitive that both not having a diagnosis, and receiving a diagnosis, can lead to poor mental health, but both offer challenges; for example, the anxiety of not knowing what is ‘wrong’ on one hand, and the shock of a poor prognosis on the other. Our study indicates that patients and carers need ongoing support in addressing the emotional challenges that a rare condition can present. Future research should focus on individuals’ experiences during these periods, and use validated tools to assess interventions.

While almost all of our survey respondents reported negative emotions in relation to their condition, many also reported positive thoughts and feelings, and they described a variety of coping mechanisms during an earlier qualitative study [20, 21]. It would be valuable to explore further what factors promote positive adjustment and coping in people living with rare diseases and

![Fig. 7](image-url)

**Fig. 7** Ways in which other sources of support are helpful. Percent of respondents who agreed or strongly agreed with answers to the question “How has this support been helpful to you?”: Patients and carers combined
any differences to those living with common chronic conditions.

**Factors affecting mental health**

An important finding from this study is that many of the drivers of poor mental health are associated with the challenges of managing a condition that is rare. This includes a lack of understanding about the condition among the public, feeling uncertain about what the future holds, and having to explain the condition to other people. Similarly, many contributing factors arising from interactions with health and other services reflected issues associated with the rarity of the condition. For example, a lack of awareness among healthcare professionals, not being believed or taken seriously, and being treated as a medical curiosity. Factors related to service access were also likely related to the rarity of the condition, in particular the way care is coordinated; it is well established that care is often poorly coordinated for rare disease patients, many of whom have complex needs and are under the care of several doctors from different specialties [4].

Our findings are consistent with previous condition- and country-specific research into the psychological impact of the process of diagnosis [33–35], and the experiences of Australian families affected by rare diseases that found that delay in diagnosis and the perceived lack of knowledge among healthcare professionals were associated with anxiety and stress [7]. This study also reported that parents perceived the lack of knowledge among clinicians to be a leading cause of diagnostic delays, highlighting an interrelation between two emotional stressors. Similarly, interviews conducted with caregivers of children with inherited metabolic conditions [14] identified emotional challenges associated with poor coordination of healthcare services and there is growing evidence about the burden of time and energy required to manage numerous appointments across different specialisms [37, 38]. Having symptoms questioned by healthcare professionals, or being mislabelled with a psychological health issue when trying to seek help for physical symptoms, have also been reported as triggers of poor mental health in specific patient populations [11].

It is known that long-term conditions significantly increase the risk of mental health issues [39, 40]. Such associations have been the subject of policy-level initiatives in the UK, such as the ‘Five Year Forward View on Mental Health’ report which emphasised the need to address the link between physical and mental health [17]. The interrelation between physical and mental health is complex and poor mental health can cause physical deterioration [41, 42]. Our findings indicate that those affected by rare conditions may face additional stressors because of the rarity of their condition. As such they may be particularly vulnerable to experiencing mental health issues.

 Patients do not live in a vacuum: our survey highlights that patients and carers face the challenges of everyday life such as financial pressures, major life events, social isolation, and employment issues along with those directly associated with their condition. It may be that such factors are exacerbated by the rarity of their conditions. For example, social isolation is likely to be a particularly pertinent issue for rare disease patients and carers due to factors such as poor understanding of the condition among the public and peers; while previous research has highlighted the considerable financial costs associated with managing rare conditions that patients and carers face [4, 43].

**Practice implications based on our findings**

The recommendations arising from this study, around the empowerment of healthcare professionals and service-level coordination, are targeted at specific government departments, advisory bodies, professional medical bodies and medical schools [20]. They are consistent with a recent international scoping review focussed on the emotional impact of the diagnostic process for rare disease which proposes improvements at both the service and individual healthcare provider level [44]. Alongside other patient organisations, healthcare professionals and NHS policy makers, Genetic Alliance UK contributed to the new UK Rare Diseases Framework which includes the aim of aligning rare disease care with wider policy development such as mental health support [19].

**Recommendations for the empowerment of healthcare professionals**

1. Healthcare professionals should be provided with the skills, knowledge and capacity to:
   - demonstrate awareness of the challenges of living with a rare disease,
   - handle discussions about mental health sensitively.

2. Healthcare professionals should routinely signpost patients and carers to sources of support.

Molster et al. advocated for greater awareness of rare diseases among clinicians, to improve the diagnostic process and ensure informational needs are met [6]. We propose that this should also extend to greater awareness of the emotional challenges of rare disease. Healthcare professionals could show greater sensitivity when delivering
a diagnosis to patients and carers, for example [7]. Our findings also indicate a need for greater sensitivity when interacting with patients without a diagnosis. This is consistent with previous studies exploring the experiences of patients living without a diagnosis [11, 12, 37].

Our respondents were clear that they would benefit from healthcare professionals asking more frequently about mental health, with the majority reporting that they are never or infrequently asked about mental health. To our knowledge this is the first study to assess the frequency of such conversations, although the finding is reflected in a report that suggests patients with rare neurological conditions are less likely to be asked about their mental health than neurology patients with more common conditions [45]. Given that many rare disease patients have frequent contact with healthcare professionals, this is alarming [4]. It is vital that healthcare professionals are provided with training so they are aware of the emotional challenges faced by their rare disease patients, they are able to communicate with sensitivity, and are equipped to handle discussions around mental health. This is underscored by our finding that while some respondents had positive experiences when discussing mental health with healthcare professionals, for others the conversations had directly caused increased levels of anxiety.

It may be that healthcare professionals would feel more comfortable raising the subject of mental health if they know that appropriate professional psychological support is available. Healthcare professionals need to be confident about how to make such referrals, but the current level of mental health service provision might be a barrier as cuts to funding of psychological support services have resulted in high thresholds for access and long waiting times [46].

Additional sources of emotional support, such as peer support and patient organisations, have been shown to be important to rare disease patients and carers; our findings support this and add detail about why it is valued [4, 5, 7]. However, in line with other studies, fewer than half of our respondents had accessed such support [4, 5]. Our survey indicates this is largely because of not knowing how to find it and that healthcare professionals are not routinely signposting to additional sources of support, possibly due to a lack of knowledge [3]. Training and professional development should therefore incorporate information about signposting.

There are resources available to help healthcare professionals signpost to support in the UK, for example on the website of Genetic Alliance UK [47]. Organisations do not exist for every rare condition, but there is a growing number of online communities (using platforms such as Facebook and Rare Connect) connecting individuals across geographical areas [48]. Online support was by far the most frequently utilised of all additional sources of support among our survey respondents.

We found that patients and carers face multiple barriers to accessing professional psychological support, such as it not being suggested by healthcare professionals, and a large majority of our respondents also felt that easier access to professional psychological support would improve their mental health. Our study echoes findings from research in Australia, the UK and across Europe [4, 6, 28]. Our findings also indicate that when professional psychological support is accessed it could be more effective and better tailored to patients’ needs. This is consistent with a survey of UK-based individuals with neurological conditions [45].

**Recommendation for service-level coordination**

3. Coordinated rare disease services should include assessment of mental health needs and access to mental health services. This should be extended to carers.

Parity of esteem is a principle in which mental health is given equal priority with physical health. Our data indicate problems with access to effective professional psychological support, and a lack of parity of esteem between physical and mental health. The gold standard for rare disease care is generally held to be coordination through multidisciplinary team working and previous studies in Australia have recommended that psychological support is “embedded in RD services” and is routinely available following diagnosis [5, 7]. We propose that assessment of mental health and a care pathway to support services, as part of coordinated care, be instigated for rare disease patients and carers in the UK. Evidence of the positive impact of psychological support for carers of people with rare diseases is growing [49].

Very few of our respondents received psychological support via specialist rare disease centres. NHS England and the UK government have made several commitments to make mental health a key healthcare focus, with promises of sustained investment, in order to ensure parity between physical and mental health [17, 18]. The new UK Rare Diseases Framework flags the need for mental healthcare to be planned alongside physical healthcare [19]. Our recommendation aligns with these national commitments and underscores the need for them to be implemented.

There is a similar need for national plans and mainstream policies to improve mental health support for rare disease patients and their carers in other nations. While 25 of the EU member states have national plans,
a commitment to improved psychological support is still lacking [50]. National policy in North America, Asia and Australia is largely focussed on research and treatment innovations, although the Canadian Organization for Rare Disorders has developed a national strategy and is calling for its implementation [51, 52]. Change in all regions may be encouraged by the recognition of rare diseases by the World Health Organization as a priority disease area, and its identification of psychosocial care as an area of unmet need [53].

The value of undertaking research into patients’ and carers’ experiences across rare diseases as a collective, in a healthcare system that is oriented towards more common diseases, has been highlighted by previous researchers, as it will “raise the profile of rare diseases and is likely to result in less duplication of efforts and resources across the range of rare diseases.” [6].

We did not set out to address the question of whether there is under-diagnosis of mental health conditions amongst rare disease patients and carers and our study does not allow us to report outcomes equivalent to a standardised screening approach, or make comparisons with other populations. However our approach has allowed for a broader understanding of patients’ and carers’ experiences of their mental health now and historically (this would not be generated by standardised tools which measure outcomes based on a very short time window). An additional strength is the inclusion of stakeholders throughout the project, on the project advisory group and through the multi-stakeholder workshop.

Our sample was self-selecting therefore it is not possible to determine the generalisability of our findings. There could be a bias toward those with more difficult experiences of mental health. Additionally, the sample was strongly biased toward women, which may be because women are more likely to respond to research requests of this nature and are more likely to take on the primary care role [28].

Further consultation with patients, carers and service providers, with experience of different types of rare disease, is needed to tailor guidelines for implementation of our recommendations. We expect that our recommendations, through feeding into national policy work, will provide the foundation for this progress to be made.

Conclusions

To our knowledge this is the largest UK-based study to systematically explore the impact of living with a rare disease on mental health. Our findings indicate a substantial impact on mental health for both patients and carers and that many drivers of poor mental health reflect issues that are specific to managing a condition that is rare. Based on our findings and discussion with stakeholders we recommend that healthcare professionals should be provided with the skills, knowledge and capacity to demonstrate an awareness of the challenges of living with a rare disease; and that healthcare professionals should routinely signpost to sources of support. We also recommend that coordinated rare disease services should include assessment of mental health needs and access to mental health services, and that this should be extended to carers. If effectively implemented, these changes could do much to address some of the mental health issues patients and carers in the UK currently face; and to ensure that mental health is considered as important as their physical health. Since our data were analysed, the covid-19 pandemic has been a significant additional stressor for the mental health and wellbeing of rare disease patients and carers, making improvements in support at a national level even more urgent [54].

Abbreviation

ERN: European Reference Networks.

Acknowledgements

We would like to acknowledge the members of the advisory group and the multi-stakeholder workshop for their input, all the patient groups who helped disseminate the survey and the individuals who participated, and Sarah Gilbert for supporting the workshop.

Authors’ contributions

RST and AH designed the study and survey. RST analysed the survey data. NM and FA led on the recommendations development; all authors contributed to the workshop output analysis. RST and AH wrote the paper, with advice from AS and feedback from the other authors. The author(s) read and approved the final manuscript.

Funding

The study was funded by public donations to Rare Disease UK, the national campaign for people with rare diseases and all who support them. Rare Disease UK is a campaign run by Genetic Alliance UK, the national charity of over 200 patient organisations, supporting all those affected by genetic conditions.

Availability of data and materials

The full survey is available on request.

Declarations

Ethics approval and consent to participate

Approval for this study was granted by the Social Care Research Ethics Committee, reference 17/IEC08/0028. Informed consent to participate in the online survey was secured via an obligatory tick box ahead of the survey questions. Participants had the option of withholding consent for use of direct quotes from any free text responses.

Consent for publication

Not applicable.

Competing interests

The authors have no competing interests to declare.

Received: 20 December 2021 Accepted: 6 May 2022

Published online: 14 May 2022
References

1. EU Research on rare diseases. https://ec.europa.eu/info/research-and-innovation/research-area/health-research-and-innovation/rare-diseases_en. Accessed 20 Dec 2021.

2. Commission of the European Communities. Communication from the commission to the European Parliament, the council, the European economic and social committee and the Committee of the Regions on rare diseases. Europe’s Challenges, 2008. https://ec.europa.eu/health/ph_threats/non_com/docs/rare_com_en.pdf. Accessed 20 Dec 2021.

3. Shire. Rare disease impact report: insights from patients and the medical community. Jersey: Shire; 2013. https://www.academia.edu/18842593/Rare_Disease_Impact_Report_Insights_from_patients_and_the_medical_community. Accessed 25 May 2021.

4. Genetic Alliance UK. Rare Experience 2020. The lived experiences of people affected by genetic, rare and undiagnosed conditions. Genetic Alliance UK, 2020. https://rareexperience2020.geneticalliance.org.uk/wp-content/uploads/2020/12/Rare-Experience-2020-Report.pdf. Accessed 25 May 2020.

5. Anderson M, Elliott EJ, Zurynski YJ. Australian families living with rare disease: experiences of diagnosis, health services use and needs for psychosocial support. Orphanet J Rare Dis. 2013;8:22.

6. Molster C, Urwin D, Di Pietro L, Fookes M, Petrie D, van der Laan S, et al. Survey of healthcare experiences of Australian adults living with rare diseases. Orphanet J Rare Dis. 2016;11:130.

7. Zurynski Y, Deverell M, Dalkeith T, Johnson S, Christodoulou J, Leonard H, et al. Australian children living with rare diseases: experiences of diagnostic and perceived consequences of diagnostic delays. Orphanet J Rare Dis. 2017;12:68.

8. Bogart KR, Irvin VL. Health-related quality of life among adults with diverse rare disorders. Orphanet J Rare Dis. 2017;12:177.

9. Bryson BA, Bogart KR. Social support, stress and life satisfaction among adults with rare diseases. Health Psychol. 2020;39:912.

10. Uhlenbusch N, Swayjan J, Holler A, Lowe B, Depping MK. Affective and anxiety disorders in patients with different rare chronic diseases: a systematic review and meta-analysis. Psychiatr Med. 2021;51:2731.

11. Nettleton S, Watt I, O’Malley L, Duffey P. Understanding the narratives of people who live with medically unexplained illness. Patient Educ Couns. 2005;56:205–10.

12. Spillmann RC, McConkie-Rosell A, Pena L, Jiang YH, Schoch K, Walley N, et al. A window into living with an undiagnosed disease: illness narratives from the undiagnosed diseases network. Orphanet J Rare Dis. 2017;12:71.

13. Somandhan D, Larkin PJ. Parents’ experiences of living with, and caring for, children, adolescents and young adults with mucopolysaccharidosis (MPS). Orphanet J Rare Dis. 2016;11:138.

14. Siddiq S, Wilson BJ, Graham ID, Lamoureux ML, Khangura SD, Tingley K, et al. Experiences of caregivers of children with inherited metabolic diseases: a qualitative study. Orphanet J Rare Dis. 2016;11:168.

15. Wu YH, Sun FK, Lee PY. Family caregivers’ lived experiences of caring for epidermolysis bullosa patients: a phenomenological study. J Clin Nursing. 2020;29:1552–60.

16. UK Department of Health and Social Care. Open Consultation. Mental health and wellbeing plan: discussion paper and call for evidence. London: Department of Health and Social Care; 2022. https://www.gov.uk/government/consultations/mental-health-and-wellbeing-plan-discussion-paper-and-call-for-evidence. Accessed 25 Apr 2022.

17. Mental health taskforce. The five year forward view for mental health. A report from the independent mental health taskforce to NHS England. Mental Health Taskforce, 2016. https://www.england.nhs.uk/wp-content/uploads/2016/02/Mental-Health-Taskforce-FYFV-final.pdf. Accessed 27 Nov 2019.

18. NICE National Institute for health and care excellence. NICE impact: mental health. National Institute for Health and Care Excellence 2019. https://www.nice.org.uk/Media/Default/About/what-we-do/Into-practice/measuring-uptake/NICEImpact-mental-health.pdf. Accessed 26 May 2021.

19. Department of Health and Social Care, Northern Ireland executive, welsh government, Scottish government. The UK rare diseases framework. HM Government, 2021. https://www.gov.uk/government/publications/uk-rare-diseases-framework/the-uk-rare-diseases-framework. Accessed 1 Feb 2022.

20. Rare disease UK. Living with a rare condition: the effect on mental health. London: Genetic Alliance UK, 2018. https://www.raredisease.org.uk/wp-content/uploads/sites/7/2018/07/living-with-a-rare-condition-the-effect-on-mental-health-pdf.pdf. Accessed 20 Dec 2021.

21. Spencer-Tansley R, Hunter A. Mental health and rare diseases: mixed methods study and policy recommendations. 9th European Conference on Rare Diseases and Orphan Products (ECRD Vienna 2018). Orphanet J Rare Dis. 2018;13:167.

22. The Neurological Alliance. Parity of esteem for people affected by neurological conditions. Watford: The Neurological Alliance, 2017. https://www.neuroall.org.uk/assets/pdfs/2017-07-parity-of-esteem.pdf. Accessed 27 May 2021.

23. Tennant R, Hiller L, Fishwick R, Platt S, Joseph S, Weich S, et al. The Warwick-Edinburgh mental well-being scale (WEMWBS): development and UK validation. Health Qual Life Outcomes. 2007;5:63–10.

24. Zimet GD, Dahlem NW, Zimet SG, Farley GK. The Multidimensional scale of perceived social support. J Personality Assessment. 1988;52:30–41.

25. Heale R, Forbes D. Understanding triangulation in research. Evid Based Nurs. 2013;16:98.

26. Office for National Statistics. Population of England and Wales. 2018. https://www.ethnicity-facts-figures.service.gov.uk/uk-population-by-ethnicity/national-and-regional-populations/population-of-england-and-wales/latest. Accessed 27 May 2021.

27. European Commission. European Reference Networks. Publications. Office of the European Union. 2017. https://ec.europa.eu/health/sites/health/files/ern/docs/2017_brochure_en.pdf. Accessed 27 May 2021.

28. EURORDIS. Juggling care and daily life: the balancing act of the rare disease community. Paris: EURORDIS, 2017. http://download2.eurordis.org.s3.amazonaws.com/rbs/2017_05_09_Social%20survey%20leaflet%20final.pdf. Accessed 27 May 2021.

29. Youssif S. The relationship between physical symptoms and health-related quality of life in oculoepharyngeal muscular dystrophy. Muscle Nerve. 2016;53:694–9.

30. Angelis A, Kanavos P, López-Bastida J, Linertová R, Oliva-Morejon R, Serrano-Aguilar P, et al. Social/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. Eur J Health Econ. 2016;17:31–42.

31. Mori Y, Downs J, Wong K, Anderson B, Epstein A, Leonard H. Impacts of caring for a child with the CDKL5 disorder on parental wellbeing and family quality of life. Orphanet J Rare Dis. 2017;12:16.

32. Boettcher J, Denecke J, Barkmann C, Wiegand-Grefe S. Quality of life and psychological functioning in children suspected for mitochondrial disease: a qualitative study. Int J Environ Res Public Health. 2020;17:8975.

33. Merker VL, Plotkin SR, Chams MP, Meterko M, Jordan JT, Elwy AR. Effective provider-patient communication of a rare disease diagnosis: a qualitative study of people diagnosed with schwannomatosis. Patient Educ Couns. 2020;104:808–14.

34. Van De Loo KFE, JaE C, Koen S, Klein IL, MCH J, Smeitink Ja M, et al. Psychological functioning in children suspected for mitochondrial disease: the need for care. Orphanet J Rare Dis. 2020;15:76.

35. Berrocoso S, Amaya I, Lázaro E, Martínez O, López-Paz JF, García M, et al. Coping with wolf-Hirschhorn syndrome: quality of life and psychosocial features of family carers. Orphanet J Rare Dis. 2020;15:293.

36. Tuno E, Ariste WJ, Meghy K, Graf S, Greene D, Shamardina O. Whole genome sequencing of rare disease patients in a national healthcare system. Nature. 2020;583:96–102.

37. Nunn R. “It’s not all in my head!” - the complex relationship between rare diseases and mental health problems. Orphanet J Rare Dis. 2017;12:29.

38. Simpson A, Bloom L, Fulop N, Hudson E, Leeson-Beever K, Morris S, et al. How are patients with rare diseases and their carers in the UK impacted by the way their care is coordinated? An exploratory qualitative interview study. Orphanet J Rare Dis. 2021;16:76.

39. The King’s Fund. Long-term conditions and mental health: the cost of co-morbidities. London: The King’s Fund, 2012. https://www.kingsfund.org.uk/sites/default/files/field_publication_file/long-term-conditions-mental-health-cost-comorbidities-naylor-feb12.pdf. Accessed 27 May 2021.

40. Royal College of Psychiatrists and Centre for Mental Health. Bridging the gap: the financial case for a reasonable rebalancing of health and care resources. Centre for Mental Health, 2013. https://www.centreformental...
health.org.uk/sites/default/files/2018-09/bridgingthegap_fullreport_0.pdf. Accessed 27 May 2021.
41. Ohnberger J, Ficher C, Sutton M. The relationship between physical and mental health: a mediation analysis. Soc Sci Med. 2017;195:42–9.
42. BMA Board of Science. Recognising the importance of physical health in mental health and intellectual disability. Achieving parity of outcomes. London: BMA; 2014. https://www.bma.org.uk/-/media/files/pdfs/workng%20for%20change/recognisingtheimportanceofphysicalhealthinmen talhealthandintellectualdisability.pdf. Accessed 27 May 2021.
43. Genetic Alliance UK. The hidden costs of rare disease. A feasibility study. London: Genetic Alliance UK; 2016. https://www.geneticalliance.org.uk/ media/2502/hiddencosts-full-report_21916-v2-1.pdf. Accessed 27 May 2021.
44. Llubes-Arria L, Sanroma-Ortiz M, Torne-Ruiz A, Carillo-Alvarez E, Garcia-Exposito J, Roca J. Emotional experience of the diagnostic process of a rare disease and the perception of support systems: a scoping review. J Clin Nurs. 2022;31:20–31.
45. The Neurological Alliance. Neuro Patience. Still waiting for improvements in treatment and care. Watford: The Neurological Alliance. https://www.neural.org.uk/wp-content/uploads/2019/07/neouro-patience-2019-1.pdf. Accessed 27 May 2021.
46. Mind. Better equipped, better care: improving mental health training for GPs and practice nurses. London: Mind; 2016. https://www.mind.org.uk/ media/5063246/find-the-words-report-better-equipped-better-care.pdf. Accessed 27 May 2021.
47. Genetic Alliance UK. https://www.geneticalliance.org.uk/. Accessed 27 May 2021.
48. EURORDIS-Rare Diseases in Europe and Care4Rare Canada. Rare Connect. https://www.rareconnect.org/. Accessed 27 May 2021.
49. Rice DB, Carboni-Jiménez A, Cañedo-Ayala M, Turner KA, Chiovitti M, Levis AW, et al. Perceived benefits and facilitators and barriers to providing psychosocial interventions for informal caregivers of people with rare diseases: a scoping review. Patient. 2020;13:471–519.
50. EURORDIS-rare diseases in Europe. Achieving holistic person-Centred care to leave no one behind: a contribution to improve the everyday lives of people living with a rare disease and their families. Paris: EURORDIS; 2019. http://download2.eurordis.org/positionpapers/Position%20Paper%20Holistic%20Care%20for%20Rare%20Diseases_Final.pdf. Accessed 27 May 2021.
51. Khosla N, Valdez R. A compilation of national plans, policies and government actions for rare diseases in 23 countries. Intractable Rare Dis Res. 2018;7:213–22.
52. Canadian Organization for Rare Diseases. Now is the time: a strategy for rare diseases is a strategy for all Canadians. Canada’s rare disease strategy. Can Org Rare Dis. 2015. https://www.raredisorders.ca/content/uploads/CORD_Canada_RD_Strategy_22May15.pdf. Accessed 27 May 2021.
53. Kaplan W, Wirtz VJ, Mantel-Teeuwisse A, Stolk P, Duthey B, Laing R. World Health Organization. Priority Medicines for Europe and the World, Update Report 2013. Chapter 6:19. 2013. https://www.who.int/medicines/areas/priority_medicines/MasterDocJune28_FINAL_web.pdf?ua=1. Accessed 20 Dec 2021.
54. Genetic Alliance UK. The rare reality of Covid-19. 2020. https://covid-19.geneticalliance.org.uk/wp-content/uploads/2020/07/Covid-19-Rare-Reality.pdf. Accessed 20 Dec 2021.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more biomedcentral.com/submissions